Chugai Turns To Digital Platform To Improve Biopharma Manufacturing
Chugai is starting to implement a new digital platform at manufacturing sites in Japan that it says will improve efficiency and flexibility.
You may also be interested in...
Chugai Building On Roche Alliance Success As It Eyes Future: CEO Okuda
In an exclusive interview with Scrip, Chugai's CEO says the now 20-year-old strategic partnership with Roche has been one of the keys to Chugai’s successful growth and has allowed smooth market expansion for both firms, as well as enabling R&D investment by the Japanese firm. A flexible, platform-based approach to R&D, rather than focusing on specific target diseases or technologies, has also benefitted Chugai, Osamu Okuda noted.
Chugai To Plow $1bn+ Into New Core R&D Site
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in early 2023 and the closure of two other long-established facilities.
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.